← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Aug 31, 2026

BioLife Solutions, Inc. (BLFS)

Healthcare • NASDAQ

$36.38

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

43.0/100

WEAK BUSINESS

BioLife Solutions, Inc. (BLFS) scores 43/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full BLFS quality analysis & detailed breakdown

VALUATION SIGNAL

N/A (Requires more data)

Requires fair value calculation and current price data

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full BLFS valuation analysis · → View full BLFS Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):AVERAGE (11.0%)

Debt-to-Equity (Solvency Risk):EXCELLENT (0.08x)

Operating Margin (Operational Efficiency):CRITICAL (-13.3%)

Return on Capital (Capital Efficiency):CRITICAL (-3.2%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

BioLife Solutions, Inc. (BLFS) stock report — Zyberno Score 43/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:36.38

Market Cap:$1.78B

Valuation Multiples (4)

P/E Ratio:

43.83x

📊 Click to view full BLFS P/E analysis →

P/B Ratio:4.23x

P/S Ratio:17.29x

Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$1.68B

Pfcf Ratio:167.13x

Price Action & Momentum (3)

12-1 Momentum:

+40.1% (72th pctile)

📈 Click to view full BLFS Momentum analysis →

Momentum Percentile:72 / 100

% of 52-Week High:95.5%

B. Profitability Assessment

Return Metrics (5)

ROE:

11.0%

📊 Click to view full BLFS ROE analysis →

ROA:10.1%

Roic:

-3.2%

📊 Click to view full BLFS ROIC analysis →

Reinvestment Rate:159.0%

Fundamental Growth Rate (g):-5.1%

Margin Analysis (3)

Operating Margin Ttm:-13.3%

Net Margin Ttm:40.6%

Ebitda Margin:-10.9%

TTM Performance (2)

Operating Margin Ttm:-13.3%

Net Margin Ttm:40.6%

Yield Metrics (2)

Earnings Yield:$2.28

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

Earnings Surprise (SUE):

+1.77

📊 Click to view full BLFS Earnings Surprise analysis →

EPS Surprise vs Expected:384.9%

Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-13.3%

Cash Flow Growth (Linear) (2)

Free Cash Flow Growth Rate (Linear):23.1%

Operating Cash Flow Growth Rate (Linear):14.6%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:9.69x

Quick Ratio:7.14x

Cash Ratio:8.11x

Leverage Analysis (3)

Debt To Equity Ttm:0.08x

Debt-to-Equity Ratio:0.08x

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:121,251,000.00

Cash And Cash Equivalents:113,100,000.00

Long Term Debt:$13.15M

Net Debt:-$97.36M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $102.82M

Linear Growth: -13.3%

📊 Click to view full BLFS Revenue analysis & methodology →

Cost Of Revenue Ttm:$34.10M

Profitability Breakdown (2)

$62.12M-$13.66M

Bottom Line Performance (3)

$41.70M

Income Before Tax:-$8.08M

Ebitda Ttm:-11,254,000.00

Operating Expenses (5)

Operating Expenses:112,780,000.00

R And D Expense:13,174,000.00

Sga Expense:45,525,000.00

Income Tax Expense:-$42.24M

Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:46.3%

Sga To Revenue Percentage:159.9%

Ebitda Margin:-10.9%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$447.49M

Current Assets:$135.20M

Ppe Net:15,235,000.00

Goodwill:208,587,000.00

Intangible Assets:$3.65M

Liability Structure (4)

Total Liabilities:27,491,000.00

Current Liabilities:13,947,000.00

Long Term Debt:$13.15M

Short Term Debt:$2.59M

Equity & Capital (3)

Equity:$420.00M

Retained Earnings:-$293.41M

Common Stock:150,000,000.00

Working Capital Items (3)

Accounts Receivable:10,652,000.00

Inventory:35,591,000.00

Accounts Payable:2,482,000.00

Special Items (2)

Contract Liabilities:188,000.00

Stock Based Compensation:3,854,000.00

C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: $17.90M

Linear Growth: 14.6%

Free cash flow TTM: $10.64M

Linear Growth: 23.1%

📊 Click to view full BLFS Free Cash Flow analysis & methodology →

Investment Activities (1)

Investing Cash Flow:-$1.83M

Financing Activities (3)

Financing Cash Flow:-$7.90M

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:2,404,000.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):0.85

$0.83

Earnings Per Share Ttm:$0.85

Revenue & Cash Per Share (2)

Sales Per Share Ttm:2.10

Operating Cash Flow Per Share:$0.41

Book Value & Capital (2)

Book Value Per Share:$8.59

Cash Per Share:2.31

Dividend Policy (1)

Dividend Payout Ratio:0.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.25x

Working Capital Turnover Ttm:0.85x

Receivables Management (2)

Receivables Turnover Ttm:9.65x

Days Sales Outstanding Ttm:37.81

Inventory Management (2)

Inventory Turnover Ttm:0.96x

Days Inventory Outstanding Ttm:381.00

Payables & Cash Cycle (2)

Days Payable Outstanding:26.57

Cash Conversion Cycle:392.25

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00

Quality Score:55.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:159.0%

Fundamental Growth Rate (g):-5.1%

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-13.3%

Cash Flow Growth Rates (2)

Free Cash Flow Growth Rate (Linear):23.1%

Operating Cash Flow Growth Rate (Linear):14.6%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-2.5%

C. Company Profile & Context

Corporate Information (6)

Symbol:BLFS

Company Name:BioLife Solutions, Inc.

Sector:Healthcare

Industry:Medical Technology

Exchange:NASDAQ

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:medium

Volume Category:N/A

Share Structure (3)

Shares Outstanding:48.87M

Shares Outstanding Basic:48.87M

Shares Outstanding Diluted:49.29M

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-08-31 18:54:13 UTC

Data Timestamp:2026-08-31T18:54:13.265317